
Quarterly report 2022-Q4
added 02-09-2023
Cardiovascular Systems Net Debt 2011-2026 | CSII
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Cardiovascular Systems
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.6 M | -68.9 M | - | -53.3 M | -95.2 M | -86.8 M | -60.6 M | -83.8 M | -124 M | -55.3 M | -18 M | -9.02 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.02 M | -124 M | -65.4 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
1.36 M | - | 1.37 % | $ 20.5 M | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.92 | -1.51 % | $ 136 M | ||
|
Alphatec Holdings
ATEC
|
442 M | $ 13.47 | -3.09 % | $ 1.93 B | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 7.2 | -6.13 % | $ 517 M | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 293.69 | -2.09 % | $ 8.29 B | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 42.43 | 2.04 % | $ 6.32 K | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
CONMED Corporation
CNMD
|
889 M | $ 42.33 | - | $ 1.31 B | ||
|
Boston Scientific Corporation
BSX
|
8.64 B | $ 73.47 | - | $ 108 B | ||
|
Abbott Laboratories
ABT
|
5.26 B | $ 113.59 | - | $ 198 B | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 13.37 | - | $ 361 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 4.9 | 6.52 % | $ 183 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 25.26 | - | $ 214 M | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 14.24 | -2.6 % | $ 1.13 B | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 103.08 | -1.97 % | $ 1.31 B | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.58 | -0.69 % | $ 122 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Integer Holdings Corporation
ITGR
|
941 M | $ 87.18 | 1.2 % | $ 2.93 B | ||
|
Globus Medical
GMED
|
-774 M | $ 88.26 | -0.52 % | $ 12 B | ||
|
Pulmonx Corporation
LUNG
|
-36.1 M | $ 1.45 | - | $ 56.7 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 11.18 | 1.82 % | $ 861 M | ||
|
Establishment Labs Holdings
ESTA
|
131 M | $ 72.72 | 0.19 % | $ 2.05 B | ||
|
Medigus Ltd.
MDGS
|
-6.43 M | - | 10.28 % | $ 55.5 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.43 | - | $ 23.1 M | ||
|
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | ||
|
Cytosorbents Corporation
CTSO
|
11.2 M | $ 0.62 | -7.43 % | $ 33.7 M | ||
|
Profound Medical Corp.
PROF
|
-7.36 M | $ 6.44 | 1.26 % | $ 180 M |